Literature DB >> 33546077

Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report.

Jinjing Wang1, Shuai Luo, Yao Li, Hong Zheng.   

Abstract

RATIONALE: Nasopharyngeal papillary adenocarcinoma is a region-specific tumor originating from the nasopharyngeal surface epithelium. Owing to its rarity, more attention has been paid to its clinicopathologic features, while little effort has been made to study the gene abnormalities that drive this tumor. We describe the first case of nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC. PATIENT CONCERNS: A 22-year-old female patient was diagnosed with nasopharyngeal papillary adenocarcinoma in our hospital, and she had right nasal obstruction for more than 6 months. Nasal endoscopy revealed a mass on the posterior roof of the nasopharynx. DIAGNOSES: Immunohistochemical staining showed that the tumor cells were diffusely positive for transcription termination factor 1, vimentin, CK19, glypican-3, and CK7, and negative for melanocyte, CK5/6, CK20, P53, P63, S100, smooth muscle actin, p16, PAX8, and thyroglobulin. The Ki-67 index was approximately 5%; EBV-encoded small nuclear RNA was negative.
INTERVENTIONS: The tumor was completely excised on endoscopy with a negative surgical margin. OUTCOMES: No sign of recurrence was observed during the 3-year follow-up period. LESSONS: Owing to its rarity, pathologists should be aware of this unusual neoplasm to avoid misdiagnosis. Further studies are needed to further characterize the relationship between ROS1-GOPC fusion and the pathogenesis of this carcinoma and its response to tyrosine kinase inhibitors in relapsed cases.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33546077      PMCID: PMC7837858          DOI: 10.1097/MD.0000000000024377

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  25 in total

1.  Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases.

Authors:  Fernando Carrizo; Mario A Luna
Journal:  Ann Diagn Pathol       Date:  2005-08       Impact factor: 2.090

2.  Endoscopic Low-Temperature Plasma Radiofrequency Ablation for Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma.

Authors:  Qing-Yao Zhong; Qiang Sun; Zhao-Hui Liu
Journal:  Ear Nose Throat J       Date:  2019-10-17       Impact factor: 1.697

3.  Lorlatinib: a new treatment option for ROS1-positive lung cancer.

Authors:  Michaël Duruisseaux
Journal:  Lancet Oncol       Date:  2019-10-25       Impact factor: 41.316

4.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What is New in the 2017 WHO Blue Book for Tumours of the Hypopharynx, Larynx, Trachea and Parapharyngeal Space.

Authors:  Nina Gale; Mario Poljak; Nina Zidar
Journal:  Head Neck Pathol       Date:  2017-02-28

5.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What Is New in the 2017 WHO Blue Book for Tumors and Tumor-Like Lesions of the Neck and Lymph Nodes.

Authors:  Nora Katabi; James S Lewis
Journal:  Head Neck Pathol       Date:  2017-02-28

6.  Clinicopathologic Characteristics of Thyroid-like Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report.

Authors:  Liang Li; Fengjuan Zhou; Fanzhong Lin; Cuihong Han
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-09

7.  Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: a novel histological finding.

Authors:  Takashi Oide; Osamu Kadosono; Jun Matsushima; Di Wu; Hiroaki Nagashima; Hideto Saigusa; Atsuko Masunaga; Yukio Nakatani; Kenzo Hiroshima
Journal:  Hum Pathol       Date:  2017-06-07       Impact factor: 3.466

8.  Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Authors:  D Moro-Sibilot; N Cozic; M Pérol; J Mazières; J Otto; P J Souquet; R Bahleda; M Wislez; G Zalcman; S D Guibert; F Barlési; B Mennecier; I Monnet; R Sabatier; S Bota; C Dubos; V Verriele; V Haddad; G Ferretti; A Cortot; F De Fraipont; M Jimenez; N Hoog-Labouret; G Vassal
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

9.  Low-Grade Nasopharyngeal Papillary Adenocarcinoma.

Authors:  Lixin Wang; Qiaoyun Min; Jingui Jiang; Yuyu Shao; Yang Cao; Daxiang Yan
Journal:  J Coll Physicians Surg Pak       Date:  2019-11       Impact factor: 0.711

10.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.

Authors:  Ana S Guerreiro Stucklin; Scott Ryall; Kohei Fukuoka; Michal Zapotocky; Alvaro Lassaletta; Christopher Li; Taylor Bridge; Byungjin Kim; Anthony Arnoldo; Paul E Kowalski; Yvonne Zhong; Monique Johnson; Claire Li; Arun K Ramani; Robert Siddaway; Liana Figueiredo Nobre; Pasqualino de Antonellis; Christopher Dunham; Sylvia Cheng; Daniel R Boué; Jonathan L Finlay; Scott L Coven; Inmaculada de Prada; Marta Perez-Somarriba; Claudia C Faria; Michael A Grotzer; Elisabeth Rushing; David Sumerauer; Josef Zamecnik; Lenka Krskova; Miguel Garcia Ariza; Ofelia Cruz; Andres Morales La Madrid; Palma Solano; Keita Terashima; Yoshiko Nakano; Koichi Ichimura; Motoo Nagane; Hiroaki Sakamoto; Maria Joao Gil-da-Costa; Roberto Silva; Donna L Johnston; Jean Michaud; Bev Wilson; Frank K H van Landeghem; Angelica Oviedo; P Daniel McNeely; Bruce Crooks; Iris Fried; Nataliya Zhukova; Jordan R Hansford; Amulya Nageswararao; Livia Garzia; Mary Shago; Michael Brudno; Meredith S Irwin; Ute Bartels; Vijay Ramaswamy; Eric Bouffet; Michael D Taylor; Uri Tabori; Cynthia Hawkins
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.